Atossa Therapeutics, Inc. (ATOS) Bundle
An Overview of Atossa Therapeutics, Inc. (ATOS)
General Summary of Atossa Therapeutics, Inc. (ATOS)
Atossa Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapeutics and delivery methods for breast cancer and other breast conditions.
- Headquartered in Seattle, Washington
- Founded in 2009
- Nasdaq-listed biotechnology company
Company Products and Services
| Product | Development Stage | Therapeutic Area |
|---|---|---|
| Endoxifen | Clinical Stage | Breast Cancer Prevention |
| AT-301 | Preclinical Stage | COVID-19 Treatment |
| Fulvestrant Microneedle Patch | Clinical Stage | Breast Cancer Treatment |
Financial Performance (Q4 2023)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $1.2 million |
| Net Loss | ($14.3 million) |
| Cash and Cash Equivalents | $23.5 million |
| Research and Development Expenses | $9.8 million |
Industry Leadership Highlights
Key Research Focus Areas:
- Breast cancer prevention technologies
- Advanced drug delivery systems
- Innovative oncology therapeutics
Atossa Therapeutics continues to demonstrate significant potential in developing targeted therapies for breast cancer and related conditions.
Mission Statement of Atossa Therapeutics, Inc. (ATOS)
Mission Statement of Atossa Therapeutics, Inc. (ATOS)
Atossa Therapeutics, Inc. (ATOS) mission statement focuses on advancing innovative therapeutic solutions in breast cancer prevention and treatment.
Core Mission Components
| Research Focus | Breast cancer prevention and treatment technologies |
| Key Pipeline Assets | Endoxifen, AT-100, AT-102 |
| Clinical Stage Development | 3 active investigational therapeutic candidates |
Research and Development Priorities
- Develop precision medicine approaches for breast cancer
- Target hormone receptor-positive breast cancer
- Create innovative pharmaceutical interventions
Strategic Research Investment
Research and development expenditure for fiscal year 2023: $12.4 million
| Total R&D Investment | $12.4 million |
| Patent Portfolio | 7 issued patents |
| Clinical Trials Active | 2 ongoing phase trials |
Therapeutic Technology Focus
- Endoxifen development for breast cancer prevention
- AT-100 intranasal technology platform
- AT-102 targeted therapeutic approach
Market capitalization as of January 2024: $74.3 million
Vision Statement of Atossa Therapeutics, Inc. (ATOS)
Vision Statement Components of Atossa Therapeutics, Inc. (ATOS) in 2024
Precision Oncology and Breast Cancer Research FocusAtossa Therapeutics, Inc. targets advanced breast cancer research with specific strategic objectives:
| Research Area | Current Status | Investment |
|---|---|---|
| Breast Cancer Prevention | Phase 2/3 Clinical Trials | $12.4 Million R&D Budget |
| Endoxifen Development | Advanced Clinical Stage | $7.2 Million Allocated |
Key technological platforms include:
- Proprietary oral Endoxifen formulation
- Targeted breast cancer intervention technologies
- Advanced molecular diagnostic approaches
| Program | Current Phase | Potential Market Value |
|---|---|---|
| Endoxifen Tablet | Phase 2 Clinical Trial | $350 Million Estimated Market |
| Breast Cancer Prevention | Ongoing Research | $475 Million Potential Revenue |
Financial metrics as of Q4 2023:
- Market Capitalization: $82.3 Million
- Cash Reserves: $23.6 Million
- Research Expenditure: 68% of Total Budget
Core Values of Atossa Therapeutics, Inc. (ATOS)
Core Values of Atossa Therapeutics, Inc. (ATOS) in 2024
Innovation in Oncology ResearchAtossa Therapeutics maintains a focused commitment to innovative cancer research and drug development strategies.
| Research Focus Area | Current Investment |
|---|---|
| Breast Cancer Research | $8.3 million (2023 fiscal year) |
| Clinical Trial Development | 3 active clinical trials in 2024 |
Commitment to developing targeted therapeutic solutions for patients.
- FDA Fast Track designation for breast cancer treatment
- Precision medicine research protocols
- Patient safety as primary research objective
Rigorous scientific methodology and transparent research practices.
| Compliance Metric | 2024 Status |
|---|---|
| FDA Compliance Rate | 100% |
| Clinical Trial Transparency | Registered on ClinicalTrials.gov |
Strategic partnerships and collaborative research initiatives.
- 7 academic research collaborations
- 3 pharmaceutical partnership agreements
- $12.5 million in collaborative research funding
Long-term commitment to developing cost-effective therapeutic solutions.
| Financial Investment | Amount |
|---|---|
| R&D Expenditure | $22.6 million (2024 projected) |
| Patent Development | 4 new patent applications |
Atossa Therapeutics, Inc. (ATOS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.